Clinical trials: Low Risk Acute Coronary Syndrome, open to volunteers
MYOCARDIAL INFARCTION
Assessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therapy Guided by Genetics Versus a Systematic High-Potency Single Antiplatelet Therapy to Neutralize Bleeding Complications in Patients With High Bleeding Risk Beyond One Month After an Acute Coronary Syndrome
Patients who suffered from acute coronary syndrome (ACS) are usually treated with a long-term dual antiplatelet therapy (DAPT) to reduce stent thrombosis and recurrent ischemic event.
- Trial name
- ADEN (NCT05577988)
- Testing
- single-antiplatelet with a low-potency antiplatelet (aspirin or clopidogrel) guided by genetic testing.
- Where
- France
- Volunteers
- 2,468 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Stable Angina (SA), Unstable Angina (UA)
Breaking Fasts Ahead of Cardiac Caths
The goal of this clinical trial is to find out whether fasting is necessary before urgent inpatient cardiac catheterizations. For patients presenting with urgent heart-related pain or even mild heart attacks, researchers want to…
- Conditions
- Stable Angina (SA), Unstable Angina (UA), NSTEMI - Non-ST Segment Elevation MI
- Trial name
- BACON-RCT (NCT06996639)
- Testing
- Non-Fasting, Fasting
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- University of South Florida
Coronary Artery Disease, Percutaneous Coronary Intervention
Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.
Patients who undergo percutaneous coronary intervention (PCI) are commonly treated with antiplatelet therapy to prevent stent thrombosis and recurrence of events.
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndromes, Antiplatelet Therapy
- Trial name
- HI-TECH 2 (NCT07582835)
- Testing
- Clopidogrel, Ticagrelor, Prasugrel
- Where
- Switzerland
- Volunteers
- 355 people
- Sponsor
- Cardiocentro Ticino
Acute Coronary Syndromes
Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up Study
The preceding IVORY trial (NCT04241601) has completed. As atherosclerosis and its complications are driven by inflammation the investigators hypothesise that treatment with low-dose IL2 may reduce adverse cardiovascular outcomes…
- Trial name
- IVORY-FINALE (NCT06427694)
- Testing
- Aldesleukin, Dextrose 5% in water
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Acute Coronary Syndromes (ACS), Acute Coronary Syndromes
Evaluation of the Effectiveness of an Interdisciplinary Intervention After Acute Coronary Syndrome on Low-Density Lipoprotein Cholesterol Levels
According to the World Health Organization (WHO), cardiovascular diseases are the worldwide leading cause of death. For the French public health, cardiovascular diseases are the leading cause of death for the women and the second…
- Trial name
- EDUSCA (NCT07178444)
- Testing
- "New" care pathway, "Standard" care pathway
- Where
- 4 sites in France
- Volunteers
- 230 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Coronary Syndrome, Unstable Angina
Treatment of ACuTe Coronary Syndromes With Low-dose colchICine
This trial is designed to evaluate whether low-dose colchicine, in addition to standard treatment recommended by guidelines, further reduces the risk of major adverse cardiovascular events in patients with acute coronary…
- Conditions
- Acute Coronary Syndrome, Unstable Angina, ST Elevation Myocardial Infarction, Non ST Segment Elevation Myocardial Infarction
- Trial name
- NCT06215989
- Testing
- Colchicine Pill
- Where
- China
- Volunteers
- 6,574 people
- Sponsor
- Beijing Anzhen Hospital
ACS (Acute Coronary Syndrome), Hyperlipidemia
Electronic Health Record Augmented LDL-Cholesterol Optimization and Control Via Active Lipid Engagement (EHR-LOCALE): A Quality Improvement Implementation Study
The purpose of this study is to determine whether a proactive, EHR-guided approach helps more individuals reach safe cholesterol levels, improves medication use, and reduces future heart attacks and strokes, compared to usual…
- Conditions
- ACS (Acute Coronary Syndrome), Hyperlipidemia, Dyslipidemia, Low-Density-Lipoprotein-cholesterol Level
- Trial name
- EHR-LOCALE (NCT07685639)
- Testing
- Pharmacist-led lipid optimization pathway
- Where
- 2 sites in Canada
- Volunteers
- 2,000 people
- Sponsor
- University of Alberta
Acute Coronary Syndromes, Dyslipidemia
Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary Syndrome
This randomized clinical trial will evaluate whether starting bempedoic acid in addition to high-intensity statin therapy and ezetimibe within 72 hours after percutaneous coronary intervention improves low-density lipoprotein…
- Trial name
- EARLY-BIRD ACS (NCT07824323)
- Testing
- bempedoic acid, Ezetimibe, High-Intensity Statin Therapy
- Where
- Taiwan
- Volunteers
- 400 people
- Sponsor
- Taipei Medical University Hospital
Coronary Artery Disease, Acute Coronary Syndromes
Aspirin 50mg vs 100mg Combined With P2Y12 Inhibitor After PCI
This is a randomized, open-label, active-controlled, non-inferiority clinical trial (the ASPIRE-LD trial) conducted in China. It aims to compare the efficacy and safety of low-dose aspirin (50 mg once daily) versus standard-dose…
- Conditions
- Coronary Artery Disease, Acute Coronary Syndromes, Chronic Coronary Syndrome, Percutaneous Coronary Intervention
- Trial name
- ASPIRE-LD (NCT07846462)
- Testing
- Aspirin, P2Y12 inhibitor
- Where
- China
- Volunteers
- 2,640 people
- Sponsor
- Jilin University
Acute Coronary Syndrome, Interventional Cardiology
Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention
The present study is aimed to compare the safety and efficacy of Ticagrelor with low-dose Aspirin versus standard dual anti-platelet therapy (DAPT) in patients with acute coronary syndrome (ACS) at high risk for ischemic events…
- Trial name
- LD-ASPIRIN (NCT04240834)
- Testing
- Aspirin, Ticagrelor
- Where
- China
- Volunteers
- 1,220 people
- Sponsor
- Fu Wai Hospital, Beijing, China